Your browser doesn't support javascript.
loading
Semaglutide effects on safety and cardiovascular outcomes in patients with overweight or obesity: a systematic review and meta-analysis.
Cleto, André Saad; Schirlo, João Matheus; Beltrame, Mayara; Gomes, Victor Hugo Oliveira; Acras, Isabela Hellmann; Neiverth, Guinter Sponholz; Silva, Breno Bach; Juliatto, Beatriz Moreira Salles; Machozeki, Janete; Martins, Camila Marinelli.
Afiliação
  • Cleto AS; State University of Ponta Grossa, Department of Medicine, Paraná, Brazil. andresaad8@gmail.com.
  • Schirlo JM; State University of Ponta Grossa, Department of Medicine, Paraná, Brazil.
  • Beltrame M; State University of Ponta Grossa, Department of Medicine, Paraná, Brazil.
  • Gomes VHO; State University of Ponta Grossa, Department of Medicine, Paraná, Brazil.
  • Acras IH; State University of Ponta Grossa, Department of Medicine, Paraná, Brazil.
  • Neiverth GS; State University of Ponta Grossa, Department of Medicine, Paraná, Brazil.
  • Silva BB; State University of Ponta Grossa, Department of Medicine, Paraná, Brazil.
  • Juliatto BMS; State University of Ponta Grossa, Department of Medicine, Paraná, Brazil.
  • Machozeki J; State University of Ponta Grossa, Department of Medicine, Paraná, Brazil.
  • Martins CM; State University of Ponta Grossa, Department of Medicine, Paraná, Brazil.
Int J Obes (Lond) ; 2024 Oct 12.
Article em En | MEDLINE | ID: mdl-39396098
ABSTRACT

BACKGROUND:

Semaglutide is a GLP-1 receptor agonist that provides a reduction in glycated hemoglobin and weight. The objective was to evaluate whether the use of semaglutide, in individuals with overweight or obesity, reduces cardiovascular outcomes and adverse effects (AE).

METHODS:

The data bases Pubmed, Lilacs, Scielo, Scopus, Web of Science and Cochrane Library were surveyed.

RESULTS:

Initially, 3333 articles were found, of which 19 articles were included. An additional search included 19 studies, totaling 38 articles. Relative risk (RR) values were significant for hospitalization due to heart failure (HF) 0.24 95% CI 0.12-0.57 (n = 2; 1045 participants; I² = 0.18), death due to cardiovascular causes 0.83 95% CI 0.71-0.98 (n = 3; 24 084 participants; I² = 0.21), death from any cause 0.79 95% CI 0.70-0.89 (n = 3; 24 084 participants; I² = 0.07), coronary revascularization 0.76 95% CI 0.69-0.85 (n = 2;20 951 participants; I² = 0.41), and non-fatal myocardial infarction 0.76 95%CI 0.66-0.88 (n = 3; 24 084 participants; I² = 0.21), with a difference between the subgroups (p = 0.05), favoring the subcutaneous administration route. The RR of stroke was 0.65 95% CI 0.44-0.97 for patients with diabetes (n = 2; 6480 participants; I² = 0.66). There was no difference between the frequency of constipation and routes of administration, as well as between doses of oral semaglutide. The RR of adverse effects was only not significant for discontinuation of treatment for oral semaglutide.

CONCLUSION:

The use of semaglutide reduced 76% in hospitalization due to HF, 17% deaths due to cardiovascular causes, 21% deaths due to any cause, 24% non-fatal myocardial infarction, 24% coronary revascularization and 35% stroke (in patients with diabetes). The use of semaglutide was associated with a higher relative risk and frequency of most adverse effects evaluated.
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Int J Obes (Lond) Assunto da revista: METABOLISMO Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Brasil País de publicação: Reino Unido
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Int J Obes (Lond) Assunto da revista: METABOLISMO Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Brasil País de publicação: Reino Unido